![Heat pre-treatment can abolish anti-drug antibody interference in ligand binding pharmacokinetic assays | AAPS Open | Full Text Heat pre-treatment can abolish anti-drug antibody interference in ligand binding pharmacokinetic assays | AAPS Open | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs41120-022-00056-3/MediaObjects/41120_2022_56_Fig2_HTML.png)
Heat pre-treatment can abolish anti-drug antibody interference in ligand binding pharmacokinetic assays | AAPS Open | Full Text
![Evaluating and Reporting the Immunogenicity Impacts for Biological Products—a Clinical Pharmacology Perspective | The AAPS Journal Evaluating and Reporting the Immunogenicity Impacts for Biological Products—a Clinical Pharmacology Perspective | The AAPS Journal](https://media.springernature.com/m685/springer-static/image/art%3A10.1208%2Fs12248-015-9857-y/MediaObjects/12248_2015_9857_Fig3_HTML.gif)
Evaluating and Reporting the Immunogenicity Impacts for Biological Products—a Clinical Pharmacology Perspective | The AAPS Journal
![A mechanistic pharmacokinetic model with drug and antidrug antibody interplay, and its application for assessing the impact of immunogenicity response on bioequivalence testing - Liao - 2020 - British Journal of Clinical A mechanistic pharmacokinetic model with drug and antidrug antibody interplay, and its application for assessing the impact of immunogenicity response on bioequivalence testing - Liao - 2020 - British Journal of Clinical](https://bpspubs.onlinelibrary.wiley.com/cms/asset/80303ddd-1980-43b0-b2d0-6856099b5c53/bcp14312-fig-0002-m.jpg)
A mechanistic pharmacokinetic model with drug and antidrug antibody interplay, and its application for assessing the impact of immunogenicity response on bioequivalence testing - Liao - 2020 - British Journal of Clinical
![Challenges of developing anti-drug antibody & concentration (PK or PD) assays for liposomal transgene enzymes on an automated immunoassay platform Challenges of developing anti-drug antibody & concentration (PK or PD) assays for liposomal transgene enzymes on an automated immunoassay platform](https://cdn.insights.bio/uploads/Figure/CC_GYPT_301WT_Figure1.png)
Challenges of developing anti-drug antibody & concentration (PK or PD) assays for liposomal transgene enzymes on an automated immunoassay platform
![On Demand Webinar - Discovery of High-Quality Anti-Idiotypic mAbs (Anti-Id) for Development of Critical PK/ADA Assay Reagents On Demand Webinar - Discovery of High-Quality Anti-Idiotypic mAbs (Anti-Id) for Development of Critical PK/ADA Assay Reagents](https://www.abveris.com/hs-fs/hubfs/custom-video-thumbnails/Screening%20Strategy%20for%20Anti-Idiotypic%20mAb%20(Anti-Id)%20as%20Critical%20PKADA%20Assay%20Reagents.png?width=331&name=Screening%20Strategy%20for%20Anti-Idiotypic%20mAb%20(Anti-Id)%20as%20Critical%20PKADA%20Assay%20Reagents.png)